J&J Advances Myeloma Domination Plan With Bispecific Tecvayli Approval
First-In-Class Approval In EU
Executive Summary
With Darzalex and Carvykti already making J&J a leader in the field, the company has added another dimension to its offering with the first multiple myeloma bispecific antibody therapy.
You may also be interested in...
CAR-T Clinical Hold Adds To 2Seventy’s Headwinds
An early stage CAR-T trial in acute myeloid leukemia has been halted after a patient death, adding to 2Seventy’s difficulties in growing sales of its myeloma treatment Abecma.
J&J Hits Another Myeloma Milestone With FDA Approval Of Talvey
The approval gives the company’s products a key presence in the myeloma space from the point of diagnosis and into later lines of disease.
J&J Adds Second Anti-BCMA Myeloma Therapy In US With Tecvayli Approval
Johnson & Johnson’s Janssen Pharmaceutical is building a multiple myeloma franchise beyond Darzalex, now with two BCMA-targeting therapies after CAR-T therapy Carvykti’s February approval.